TargetBeta
IL15
interleukin 15 · also IL-15, MGC9721 · Interleukins
6 programs in company-led studies act on IL15, from 6 companies: 2 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| nogapendekin alfa inbakiceptrule | ImmunityBio | phase 3 | 4512 running | IL15RA, IL2RB, IL2RG | NCIt |
| efserakefusp alfa | Jiangsu HengRui Medicine | phase 3 | 64 running | – | the company's pipeline |
| belacabnagene franleucelrule | Nkarta | phase 2 | 33 running | CD19 | NCIt |
| GIA632 | Novartis | phase 2 | 33 running | – | the company's pipeline |
| SPGL008rule | 3SBio | phase 2 | 33 running | IL15RA | the studies' text |
| Daxokafusp Alfa | Sanofi | phase 2 | 22 running | IL2, PDCD1 | the company's pipeline |
Conditions their studies are in
- Non-Muscle Invasive Bladder Neoplasms, 3 programs
- Carcinoma, Non-Small-Cell Lung, 2 programs
- Carcinoma, Transitional Cell, 1 program
- Dermatitis, Atopic, 1 program
- Lichen Planus, 1 program
- Lupus Nephritis, 1 program
- Lymphoma, Mantle-Cell, 1 program
- Neoplasms, 1 program
- Pancreatic Neoplasms, 1 program
- Scleroderma, Systemic, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026nogapendekin alfa inbakicept · ImmunityBio · phase 3 · NCT06829823
- Jan 19, 2027Daxokafusp Alfa · Sanofi · phase 2 · NCT05584670
- Apr 2027belacabnagene franleucel · Nkarta · phase 2 · NCT06557265
- May 17, 2027GIA632 · Novartis · phase 2 · NCT07220577
- Nov 2027SPGL008 · 3SBio · phase 2 · NCT07874984
- Dec 2027efserakefusp alfa · Jiangsu HengRui Medicine · phase 3 · NCT07073534
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.